Prior trial data [6, 9] showed a numerically higher ORR in patients with PD-L1–positive RM-NPC than in those with PD-L1–negative tumors; and high-PD-L1 expression was associated with better survival outcomes in both NPC and other head and neck cancer [13, 14]. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.